Pathogenic role of CCL2/MCP-1 in scleroderma.

Scleroderma is a connective tissue disease with unknown etiology characterized by excessive deposition of extracellular matrix in the skin. Cellular infiltrates of certain immune cells and proinflammatory mediators are suggested to play a crucial role in cutaneous fibrosis, forming complicated networks between fibroblasts and immune cells via cell-cell communications. Tissue-selective trafficking of leukocytes is mediated by combinations of adhesion molecules and chemokines. Recent studies have shown that an increase in proinflammatory chemokines has been associated with the initiation and/or development of fibrotic condition, suggesting that chemokines and their receptors may be important mediators of inflammation and fibrosis in scleroderma. In particular, CCL2/monocyte chemoattractant protein-1 (MCP-1) has been suggested to play an important role in scleroderma. This review will focus on the roles of CCL2 and its receptor during the process of cutaneous sclerosis, and also provide a current insight into the potential mechanisms of scleroderma.

[1]  T. Yoshikawa,et al.  SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Xiaofeng Zhu,et al.  Diminished induction of skin fibrosis in mice with MCP-1 deficiency. , 2006, The Journal of investigative dermatology.

[3]  D. Abraham,et al.  Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. , 2005, Arthritis and rheumatism.

[4]  D. Wakefield,et al.  Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma , 2005, Experimental dermatology.

[5]  F. Sampogna,et al.  Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement , 2004, Clinical and experimental immunology.

[6]  W. Kuziel,et al.  C‐C chemokine receptor 2 (CCR2) deficiency improves bleomycin‐induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage‐derived matrix metalloproteinases , 2004, The Journal of pathology.

[7]  A. Takeshita,et al.  Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[8]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. VI: Evaluation of bleomycin-induced skin sclerosis in nude mice , 2004, Archives of Dermatological Research.

[9]  P. Sime,et al.  Expression of CD154 (CD40 Ligand) by Human Lung Fibroblasts: Differential Regulation by IFN-γ and IL-13, and Implications for Fibrosis1 , 2004, The Journal of Immunology.

[10]  N. Lukacs,et al.  Chemokines and asthma. , 2003, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[11]  N. Kamatani,et al.  Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40‐CD154 in the phenotype of SSc fibroblasts , 2003, European journal of immunology.

[12]  Toshiyuki Yamamoto,et al.  Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. , 2003, The Journal of investigative dermatology.

[13]  D. Abraham,et al.  Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. , 2003, Arthritis and rheumatism.

[14]  T. Yamamoto,et al.  Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis. , 2003, Clinical and experimental rheumatology.

[15]  U. Müller-Ladner,et al.  Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis , 2002, Modern rheumatology.

[16]  L. McCormick,et al.  Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation1 , 2002, The Journal of Immunology.

[17]  B. Ma,et al.  IL-13-Induced Chemokine Responses in the Lung: Role of CCR2 in the Pathogenesis of IL-13-Induced Inflammation and Remodeling1 , 2002, The Journal of Immunology.

[18]  S. Wilt,et al.  Synergy Between CD40 Ligation and IL-4 on Fibroblast Proliferation Involves IL-4 Receptor Signaling1 , 2002, The Journal of Immunology.

[19]  M. Landthaler,et al.  Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. , 2001, Arthritis and rheumatism.

[20]  T. Moore,et al.  Protection from Pulmonary Fibrosis in the Absence of CCR2 Signaling1 , 2001, The Journal of Immunology.

[21]  T. Yamamoto,et al.  High expression and autoinduction of monocyte chemoattractant protein‐1 in scleroderma fibroblasts , 2001, European journal of immunology.

[22]  K. Nishioka,et al.  Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. , 2001, The Journal of investigative dermatology.

[23]  P. Holt,et al.  Regulation of Dendritic Cell Recruitment into Resting and Inflamed Airway Epithelium: Use of Alternative Chemokine Receptors as a Function of Inducing Stimulus1 , 2001, The Journal of Immunology.

[24]  T. Yamamoto,et al.  Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. , 2001, Journal of dermatological science.

[25]  J. Alcamí,et al.  Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. , 2001, Arthritis and rheumatism.

[26]  I. Rosner,et al.  THU0032 The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity , 2001 .

[27]  T. Yamamoto,et al.  Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis. , 2001, Journal of dermatological science.

[28]  Yongbok Kim,et al.  Enhanced Airway Th2 Response After Allergen Challenge in Mice Deficient in CC Chemokine Receptor-2 (CCR2)1 , 2001, The Journal of Immunology.

[29]  J. Martin-Serrano,et al.  Hypoxia induces expression of the chemokines monocyte chemoattractant protein‐1 (MCP‐1) and IL‐8 in human dermal fibroblasts , 2001, Clinical and experimental immunology.

[30]  M. Baggiolini,et al.  Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. , 2000, Blood.

[31]  S. Breit,et al.  Analysis of dendritic cell populations using a revised histological staging of morphoea , 2000, The British journal of dermatology.

[32]  T. Yamamoto,et al.  Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts , 2000, Archives of Dermatological Research.

[33]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains , 2000, Archives of Dermatological Research.

[34]  Toshiyuki Yamamoto,et al.  Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.

[35]  Hirai,et al.  Interleukin‐13 and tumour necrosis factor‐α synergistically induce eotaxin production in human nasal fibroblasts , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  L. Lichtenstein,et al.  Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. , 2000, The Journal of pharmacology and experimental therapeutics.

[37]  C. Martínez-A,et al.  Cc Chemokine Receptor (Ccr)3/Eotaxin Is Followed by Ccr4/Monocyte-Derived Chemokine in Mediating Pulmonary T Helper Lymphocyte Type 2 Recruitment after Serial Antigen Challenge in Vivo , 2000, The Journal of experimental medicine.

[38]  E. Bröcker,et al.  Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein‐1 is correlated with recruitment of mast cells which synthesize interleukin‐4 in vivo , 2000, The Journal of pathology.

[39]  K. Nishioka,et al.  Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. , 1999, The Journal of rheumatology.

[40]  Yan Zhang,et al.  Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. , 1999, Journal of immunology.

[41]  K. Nishioka,et al.  Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. , 1999, The Journal of investigative dermatology.

[42]  M. Takigawa,et al.  Role and interaction of connective tissue growth factor with transforming growth factor‐β in persistent fibrosis: A mouse fibrosis model , 1999, Journal of cellular physiology.

[43]  P. Allavena,et al.  Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells , 1999, Journal of leukocyte biology.

[44]  F. Jirik,et al.  A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. , 1999, Cellular immunology.

[45]  R. Strieter,et al.  Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. , 1999, Journal of immunology.

[46]  Sato,et al.  Augmented production of chemokines (monocyte chemotactic protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α) and MIP‐1β) in patients with systemic sclerosis: MCP‐1 and MIP‐1α may be involved in the development of pulmonary fibrosis , 1999 .

[47]  K. Kubo,et al.  Bleomycin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. , 1999, Journal of immunology.

[48]  H. Mizutani,et al.  Increased cutaneous immunoreactive stem cell factor expression and serum stem cell factor level in systemic scleroderma. , 1999, Journal of dermatological science.

[49]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. , 1999, The Journal of investigative dermatology.

[50]  K. Nishioka,et al.  Expression of Stem Cell Factor in the Lesional Skin of Systemic Sclerosis , 1998, Dermatology.

[51]  C. Caux,et al.  Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites , 1998, The Journal of experimental medicine.

[52]  M. Baggiolini Chemokines and leukocyte traffic , 1998, Nature.

[53]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[54]  S. Milani,et al.  Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. , 1998, The American journal of pathology.

[55]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[56]  G. Pizzolo,et al.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. , 1997, The American journal of pathology.

[57]  Michael R. Müller,et al.  The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. , 1997, Blood.

[58]  R. Strieter,et al.  C-C chemokines differentially alter interleukin-4 production from lymphocytes. , 1997, The American journal of pathology.

[59]  D. Salant,et al.  RANTES and Monocyte Chemoattractant Protein–1 (MCP-1) Play an Important Role in the Inflammatory Phase of Crescentic Nephritis, but Only MCP-1 Is Involved in Crescent Formation and Interstitial Fibrosis , 1997, The Journal of experimental medicine.

[60]  A. Rosen,et al.  Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis , 1997, The Journal of experimental medicine.

[61]  S. Phan,et al.  Costimulation of Fibroblast Collagen and Transforming Growth Factor β1 Gene Expression by Monocyte Chemoattractant Protein-1 via Specific Receptors* , 1996, The Journal of Biological Chemistry.

[62]  E. Everett,et al.  Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[63]  S. Phan,et al.  Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. , 1994, Journal of immunology.

[64]  A. Takeshita,et al.  Interleukin-4 acts as a potent stimulator for expression of monocyte chemoattractant JE/MCP-1 in mouse peritoneal macrophages. , 1994, Biochemical and biophysical research communications.

[65]  T. Mak,et al.  A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice , 1994, European journal of immunology.

[66]  G. Sempowski,et al.  Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. , 1994, Journal of immunology.

[67]  C. Bona,et al.  Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. , 1993, Journal of autoimmunity.

[68]  D. Schadendorf,et al.  Human mast cells produce IL-8. , 1993, Journal of immunology.

[69]  T. Whiteside,et al.  Cytokine production and serum levels in systemic sclerosis. , 1992, Clinical immunology and immunopathology.

[70]  T. Schall,et al.  RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes , 1992, The Journal of experimental medicine.

[71]  H. Katai,et al.  Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. , 1992, The Journal of clinical investigation.

[72]  O. Ishikawa,et al.  Macrophage infiltration in the skin of patients with systemic sclerosis. , 1992, The Journal of rheumatology.

[73]  A. J. Valente,et al.  Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[74]  J. Banchereau,et al.  Interleukin‐4 stimulates collagen gene expression in human fibroblast monolayer cultures Potential role in fibrosis , 1992, FEBS letters.

[75]  N. Sepp,et al.  Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. , 1991, Immunobiology.

[76]  K. Fredens,et al.  Eosinophil activation in systemic sclerosis. , 1991, Arthritis and rheumatism.

[77]  R. Silver,et al.  A STRATEGY FOR DETERMINING THE PATHOGENESIS OF SYSTEMIC SCLEROSIS: Is Transforming Growth Factor β the Answer? , 1989, Arthritis and rheumatism.

[78]  J. Massagué,et al.  Regulation of cell adhesion receptors by transforming growth factor-beta. Regulation of vitronectin receptor and LFA-1. , 1989, The Journal of biological chemistry.

[79]  B. Rollins,et al.  Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[80]  T. Krieg,et al.  Localization of collagen mRNA in normal and scleroderma skin by in‐situ hybridization , 1988, European journal of clinical investigation.

[81]  M. Laiho,et al.  Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. , 1987, The Journal of biological chemistry.

[82]  K. S. Ramesh,et al.  Eosinophils stimulate fibroblast DNA synthesis. , 1987, Blood.

[83]  J. Heath,et al.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. , 1987, The EMBO journal.

[84]  K. Nishioka,et al.  Mast cell numbers in diffuse scleroderma. , 1987, Archives of dermatology.

[85]  M. Laiho,et al.  Enhanced production and extracellular deposition of the endothelial- type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta , 1986, The Journal of cell biology.

[86]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[88]  T. Krieg,et al.  Collagen Synthesis by Scleroderma Fibroblasts a , 1985, Annals of the New York Academy of Sciences.

[89]  R. Clark,et al.  Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. , 1985, Cellular immunology.

[90]  R. Clark,et al.  Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? , 1985, Annals of internal medicine.

[91]  J. R. Reeves,et al.  Cellular infiltrates in scleroderma skin. , 1977, Arthritis and rheumatism.

[92]  E. Leroy,et al.  Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. , 1974, The Journal of clinical investigation.

[93]  N Rowell,et al.  Systemic sclerosis. , 1968, British medical journal.

[94]  K. Flanders,et al.  Cellular Localization of Transforming Growth Factor-f3 Expression In Bleomycin-Induced Pulmonary Fibrosis , 2007 .

[95]  T. Krieg,et al.  [Pathogenesis of systemic sclerosis]. , 2007, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[96]  U. Müller-Ladner,et al.  Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. , 2006, Arthritis and rheumatism.

[97]  M. Inaoki,et al.  Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. , 2005, Journal of cellular physiology.

[98]  T. Birkland,et al.  Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts , 2004, Archives of Dermatological Research.

[99]  Yong Woo Lee,et al.  Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. , 2003, American journal of physiology. Heart and circulatory physiology.

[100]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. , 2002, Clinical immunology.

[101]  W. Paul,et al.  Lack of Skin Fibrosis in Tight Skin (TSK) Mice with Targeted Mutation in the Interleukin-4Rα and Transforming Growth Factor-β Genes , 2001 .

[102]  A. Gabrielli,et al.  Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion. , 1999, The Journal of investigative dermatology.

[103]  G. Canonica,et al.  INTERLEUKIN (IL)-4 AND IL-13 ACT ON HUMAN LUNG FIBRO-BLAST , 1998 .

[104]  K. Takehara,et al.  Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor beta--simultaneous application with basic fibroblast growth factor causes persistent fibrosis. , 1997, Biochemical and biophysical research communications.

[105]  S. Jimenez,et al.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology (Basel).

[106]  T. Krieg,et al.  Control of fibrosis in systemic scleroderma. , 1993, The Journal of investigative dermatology.

[107]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[108]  E. Kovacs Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. , 1991, Immunology today.

[109]  R. Harley,et al.  Ketotifen prevents skin fibrosis in the tight skin mouse. , 1990, The Journal of rheumatology.

[110]  R. Harley,et al.  Inhibition of fibrosis in TSK mice by blocking mast cell degranulation. , 1987, The Journal of rheumatology.

[111]  R. Fleischmajer,et al.  Systemic scleroderma. , 1970, Archives of dermatology.

[112]  Marikki LaihoSQ,et al.  Transforming Growth Factor + Induction of Type-1 Plasminogen Activator Inhibitor , 2022 .